PL2710039T3 - Kompozycje przeciwko CGRP i ich zastosowanie - Google Patents

Kompozycje przeciwko CGRP i ich zastosowanie

Info

Publication number: PL2710039T3
Authority: PL; Poland
Prior art keywords: cgrp compositions; cgrp; compositions
Prior art date: 2011-05-20

Application number

PL12789693T

Other languages

English (en)

Inventor

Brian Robert KOVACEVICH

Leon F. Garcia-Martinez

Katie Olson

Benjamin H. Dutzar

Jens J. BILLGREN

John A. Latham

Danielle M. Mitchell

Patricia Dianne Mcneill

Nicole M. JANSON

Maria-Cristina LOOMIS

Original Assignee

Alderbio Holdings Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-20

Filing date

2012-05-21

Publication date

2019-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2710039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-21 Application filed by Alderbio Holdings Llc filed Critical Alderbio Holdings Llc

2019-07-31 Publication of PL2710039T3 publication Critical patent/PL2710039T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL12789693T 2011-05-20 2012-05-21 Kompozycje przeciwko CGRP i ich zastosowanie PL2710039T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161488660P	2011-05-20	2011-05-20
PCT/US2012/038844 WO2012162243A2 (en)	2011-05-20	2012-05-21	Anti-cgrp compositions and use thereof
EP12789693.4A EP2710039B1 (en)	2011-05-20	2012-05-21	Anti-cgrp compositions and use thereof

Publications (1)

Publication Number	Publication Date
PL2710039T3 true PL2710039T3 (pl)	2019-07-31

Family

ID=47175055

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18203518T PL3495392T3 (pl)	2011-05-20	2012-05-21	Kompozycje anty-cgrp i ich zastosowanie
PL12789693T PL2710039T3 (pl)	2011-05-20	2012-05-21	Kompozycje przeciwko CGRP i ich zastosowanie
PL19215303T PL3662932T3 (pl)	2011-05-20	2012-05-21	Kompozycje anty-cgrp i i ch zastosowanie

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL18203518T PL3495392T3 (pl)	2011-05-20	2012-05-21	Kompozycje anty-cgrp i ich zastosowanie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL19215303T PL3662932T3 (pl)	2011-05-20	2012-05-21	Kompozycje anty-cgrp i i ch zastosowanie

Country Status (38)

Country	Link
US (10)	US9745373B2 (pl)
EP (5)	EP3662932B1 (pl)
JP (3)	JP6282584B2 (pl)
KR (1)	KR102128627B1 (pl)
CN (5)	CN107602700B (pl)
AP (1)	AP2013007259A0 (pl)
AR (3)	AR086516A1 (pl)
AU (3)	AU2012258966C1 (pl)
BR (2)	BR112013029932A2 (pl)
CA (3)	CA3080000A1 (pl)
CL (3)	CL2013003336A1 (pl)
CO (1)	CO6870005A2 (pl)
CY (2)	CY1124209T1 (pl)
DK (3)	DK2710039T3 (pl)
EA (3)	EA201891284A1 (pl)
ES (3)	ES2873837T3 (pl)
FR (1)	FR22C1032I2 (pl)
HR (3)	HRP20190640T1 (pl)
HU (4)	HUE054437T2 (pl)
IL (4)	IL229431B (pl)
LT (4)	LT2710039T (pl)
LU (1)	LUC00270I2 (pl)
MX (3)	MX370749B (pl)
NL (1)	NL301181I2 (pl)
NO (1)	NO2022029I1 (pl)
NZ (1)	NZ733060A (pl)
PE (2)	PE20141787A1 (pl)
PH (2)	PH12013502405B1 (pl)
PL (3)	PL3495392T3 (pl)
PT (3)	PT2710039T (pl)
RS (3)	RS62306B1 (pl)
SG (2)	SG10201604040PA (pl)
SI (3)	SI3495392T1 (pl)
SM (3)	SMT201900293T1 (pl)
TR (1)	TR201904088T4 (pl)
TW (4)	TWI646111B (pl)
WO (1)	WO2012162243A2 (pl)
ZA (1)	ZA201308637B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007054809A2 (en)	2005-11-14	2007-05-18	Rinat Neuroscience Corp.	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
NZ587292A (en)	2008-03-04	2012-09-28	Pfizer Ltd	Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
SMT201900293T1 (it)	2011-05-20	2019-07-11	Alderbio Holdings Llc	Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en)	2011-05-20	2024-11-06	H. Lundbeck A/S	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
DK2709662T3 (da)	2011-05-20	2019-11-04	Alderbio Holdings Llc	Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
TWI670279B (zh)	2013-03-15	2019-09-01	美商艾爾德生物製藥股份有限公司	抗體純化及純度監測
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
EP3016684B1 (en) *	2013-07-03	2022-02-23	H. Lundbeck A/S	Regulation of glucose metabolism using anti-cgrp antibodies
CN111973740A (zh)	2014-03-21	2020-11-24	泰华制药国际有限公司	针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016168757A1 (en)	2015-04-16	2016-10-20	Alder Biopharmaceuticals, Inc.	Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
HK1258385A1 (zh) *	2015-09-24	2019-11-08	泰瓦制药国际有限公司	预防、治疗和减轻(持续性)创伤後头痛
TW201725212A (zh) *	2015-12-10	2017-07-16	第一三共股份有限公司	特異性於降鈣素基因相關胜肽的新穎蛋白
CN108473567A (zh) *	2016-01-28	2018-08-31	伊莱利利公司	Cgrp抗体及其用途
EP3411066A1 (en)	2016-02-01	2018-12-12	Eli Lilly and Company	Parathyroid hormone anti-rankl antibody fusion compounds
JP7116685B2 (ja)	2016-04-15	2022-08-10	エイチ．ルンドベックアー／エス	ヒト化抗ｐａｃａｐ抗体及びそれらの使用
CA3036632A1 (en)	2016-09-23	2018-03-29	Teva Pharmaceuticals International Gmbh	Treating refractory migraine
KR20190067181A (ko)	2016-09-23	2019-06-14	테바 파마슈티컬스 인터내셔널 게엠베하	군발성 두통의 치료
US20190071490A1 (en)	2017-03-02	2019-03-07	Beth Israel Deaconess Medical Center, Inc.	Preventing Post-Ictal Headaches
JP2020517644A (ja) *	2017-04-19	2020-06-18	マンセル、ジョン	疼痛障害の治療のための組成物および方法
EP3737699A1 (en)	2018-01-12	2020-11-18	Amgen Inc.	Pac1 antibodies and uses thereof
US11274158B2 (en) *	2018-01-30	2022-03-15	Flagship Pioneering Innovations V, Inc.	Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN112040949A (zh) *	2018-02-23	2020-12-04	瑞美德生物医药科技有限公司	降钙素基因相关肽(cgrp)拮抗剂抗体
WO2019231800A1 (en) *	2018-05-31	2019-12-05	Eli Lilly And Company	Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) *	2018-09-13	2021-01-26	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) *	2018-12-26	2020-07-01	Life Length S.L.	Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
PE20211708A1 (es) *	2019-01-08	2021-09-01	H Lundbeck As	Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
EP3908606A4 (en)	2019-01-08	2022-11-23	H. Lundbeck A/S	ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
US12371453B2 (en)	2019-02-28	2025-07-29	HLB Science Inc.	Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
WO2020222892A1 (en) *	2019-05-02	2020-11-05	Alder Biopharmaceuticals, Inc.	Treatment of headache using anti-cgrp antibodies
CN114127110B (zh) *	2019-05-30	2022-07-01	山东博安生物技术股份有限公司	抗cgrp抗体及其应用
BR102020007149A8 (pt) *	2020-04-06	2023-09-26	H Lundbeck As	Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
KR20230157986A (ko)	2021-03-02	2023-11-17	체게에르페 다이어그노스틱스 게엠베하	편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
KR20240049275A (ko)	2021-08-27	2024-04-16	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용한 군발성 두통의 치료
AU2023223603A1 (en)	2022-02-28	2024-08-22	Tridem Bioscience Gmbh & Co Kg	A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4570913A1 (en) *	2022-08-11	2025-06-18	Shanghai Junshi Biosciences Co., Ltd.	Anti-cgrp antibody and use
IT202300010371A1 (it) *	2023-05-23	2024-11-23	Alberto Chiarugi	Inibitori della crescita tumorale
CN120899912A (zh) *	2024-05-07	2025-11-07	中国人民解放军军事科学院军事医学研究院	一种治疗自身免疫性疾病的方法和应用
CN118271438B (zh) *	2024-05-27	2024-08-30	上海宏成药业有限公司	抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3662333A (en)	1970-09-08	1972-05-09	Bendix Corp	Hydraulic accumulator charge detector and indicating system
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5123197A (ja)	1974-08-21	1976-02-24	Hitachi Ltd	Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DE134631T1 (de) *	1983-06-15	1985-12-05	Roger Kingdom Craig	Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
JPS62129297A (ja)	1985-08-09	1987-06-11	Toyo Jozo Co Ltd	カルシトニン遺伝子関連ペプチド誘導体
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US5266561A (en)	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
US5364841A (en)	1988-01-11	1994-11-15	Amylin Pharmaceuticals, Inc.	Treatment of obesity and essential hypertension and related disorders
CA2006596C (en)	1988-12-22	2000-09-05	Rika Ishikawa	Chemically-modified g-csf
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5766883A (en)	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
FR2669336B1 (fr)	1990-11-20	1993-01-22	Adir	Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) *	1992-08-19	1994-02-03	Henning Berlin Gmbh	Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en)	1993-03-19	1994-09-29	Duke University	Method of treatment of tumors with an antibody binding to tenascin
US5436265A (en)	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5475995A (en)	1994-05-16	1995-12-19	Livingston; George G.	Truck spare tire locking rod
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
DE69534530T2 (de)	1994-08-12	2006-07-06	Immunomedics, Inc.	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
JPH10504457A (ja)	1994-08-16	1998-05-06	ヒューマンジノームサイエンシーズ，インコーポレイテッド	カルシトニンレセプター
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr)	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en)	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en)	1995-05-22	1997-06-17	Merck Frosst Canada, Inc.	N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
JPH11512396A (ja)	1995-09-05	1999-10-26	スミスクライン・ビーチャム・コーポレイション	化合物および方法
US5710024A (en) *	1996-07-23	1998-01-20	Smithkline Beecham Corporation	Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
EP0934068A1 (en)	1996-09-09	1999-08-11	Smithkline Beecham Corporation	Compounds and methods
DK0927192T3 (da)	1996-09-10	2004-09-13	Boehringer Ingelheim Pharma	Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
US6653104B2 (en)	1996-10-17	2003-11-25	Immunomedics, Inc.	Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en)	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
JP2002525371A (ja)	1998-09-30	2002-08-13	メルクシャープエンドドームリミテッド	Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
AU1219000A (en)	1998-10-22	2000-05-08	Regents Of The University Of California, The	Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1031350A1 (en)	1999-02-23	2000-08-30	Warner-Lambert Company	Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en)	1999-03-02	2001-11-06	Boehringer Ingelheim Pharma Kg	Antagonists of calcitonin gene-related peptide
US6521609B1 (en)	1999-08-10	2003-02-18	Boehringer Ingelheim Pharma Kg	Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
UA77152C2 (en)	1999-09-25	2006-11-15		Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
AU4002001A (en)	2000-03-01	2001-09-12	Med Immune Inc	High potency recombinant antibodies and method for producing them
US6406863B1 (en)	2000-06-23	2002-06-18	Genetastix Corporation	High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en)	2001-03-06	2002-10-31	Anne-Marie Salmon	Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en)	2001-08-17	2003-09-25	Boehringer Ingelheim Pharma Kg	Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CA2471833A1 (en)	2001-11-26	2003-06-05	Protemix Corporation Limited	Methods of compositions for normalizing lipid levels in mammalian tissues
SI1527100T1 (sl)	2002-03-29	2009-12-31	Schering Corp	Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
EP1501929B1 (de)	2002-05-06	2013-03-27	Noxxon Pharma AG	Cgrp bindende nukleinsäuren
US20040110170A1 (en)	2002-05-18	2004-06-10	The Regents Of The University Of California	Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en)	2002-05-21	2008-03-18	Allergan, Inc.	Methods and compositions for alleviating pain
KR20050008790A (ko)	2002-06-05	2005-01-21	브리스톨-마이어스 스큅 컴퍼니	칼시토닌 유전자 관련 펩티드 수용체 길항제
DE60305919T2 (de)	2002-06-28	2007-01-18	Domantis Limited, Cambridge	Dual-specifische liganden mit erhöhter halbwertszeit
BR0313388A (pt)	2002-08-12	2005-07-05	Birkir Sveinsson	Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de)	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2508375C (en)	2002-12-02	2014-05-27	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
CA2511598C (en)	2002-12-24	2016-09-13	Rinat Neuroscience Corp.	Anti-ngf antibodies and methods using same
ATE509019T1 (de)	2003-03-14	2011-05-15	Merck Sharp & Dohme	Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
CA2518852A1 (en)	2003-03-14	2004-09-30	Merck & Co., Inc.	Monocyclic anilide spirohydantoin cgrp receptor antagonists
WO2004082602A2 (en)	2003-03-14	2004-09-30	Merck & Co. Inc.	Carboxamide spirohydantoin cgrp receptor antagonists
JP4673294B2 (ja)	2003-03-14	2011-04-20	メルク・シャープ・エンド・ドーム・コーポレイション	二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
ATE516803T1 (de)	2003-03-14	2011-08-15	Merck Sharp & Dohme	Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
AU2004229518B2 (en)	2003-04-15	2010-02-18	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
JO2355B1 (en)	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en)	2003-04-29	2004-11-11	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US20060173046A1 (en)	2003-07-15	2006-08-03	Bell Ian M	Hydroxypyridine cgrp receptor antagonists
DK1678314T3 (da) *	2003-10-22	2012-12-03	Keck Graduate Inst	Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
US20080070239A1 (en)	2003-10-29	2008-03-20	University Of Rochester	Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en)	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en)	2004-04-15	2007-10-09	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de)	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TWI432196B (zh)	2005-01-18	2014-04-01	Euro Celtique Sa	內臟痛的治療
EP1770091A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2619856A1 (en)	2005-08-25	2007-03-01	Wex Pharmaceuticals Inc.	Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070108378A1 (en)	2005-11-14	2007-05-17	Toru Terabayashi	High pressure optical cell for a downhole optical fluid analyzer
WO2007054809A2 (en) *	2005-11-14	2007-05-18	Rinat Neuroscience Corp.	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007061676A2 (en)	2005-11-18	2007-05-31	Merck & Co., Inc.	Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) *	2005-12-22	2007-07-05	Eli Lilly And Company	Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en)	2006-03-27	2015-07-07	John R. Ramun	Universal control scheme for mobile hydraulic equipment and method for achieving the same
AU2007307324B2 (en)	2006-05-19	2013-08-15	Alder Biopharmaceuticals, Inc.	Culture method for obtaining a clonal population of antigen-specific B cells
BRPI0712492A2 (pt)	2006-06-08	2012-08-21	Boehringer Ingelheim Int	uso de antagonistas de cgpr e composição farmacêutica compreendendo antagonistas de cgpr.
CA2658573A1 (en)	2006-07-21	2008-01-24	Vertex Pharmaceuticals Incorporated	Cgrp receptor antagonists
US8075902B2 (en) *	2007-01-03	2011-12-13	Michael Powell	Diagnosis and treatment of cancer related to human dormancy
TWI617576B (zh)	2007-05-21	2018-03-11	艾爾德生物控股有限責任公司	介白素-６（ｉｌ-６）的抗體及其等之用途
CN101868477A (zh)	2007-05-21	2010-10-20	奥尔德生物制药公司	新型兔抗体人源化方法和人源化的兔抗体
TW201531484A (zh)	2007-05-21	2015-08-16	Alder Biopharmaceuticals Inc	抗ＴＮＦ-α之抗體及其用途
GB0725103D0 (en) *	2007-12-21	2008-01-30	Glaxo Group Ltd	Novel compounds
WO2009109908A1 (en)	2008-03-04	2009-09-11	Pfizer Limited	Methods of treating inflammatory pain
NZ587292A (en)	2008-03-04	2012-09-28	Pfizer Ltd	Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
RU2535074C2 (ru) *	2009-08-28	2014-12-10	Лэйбрис Байолоджикс, Инк.	Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
AR081434A1 (es)	2010-06-10	2012-08-29	Lilly Co Eli	Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) *	2010-12-01	2022-01-04	H. Lundbeck A/S	High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
DK2709662T3 (da)	2011-05-20	2019-11-04	Alderbio Holdings Llc	Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
SMT201900293T1 (it)	2011-05-20	2019-07-11	Alderbio Holdings Llc	Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en)	2011-05-20	2024-11-06	H. Lundbeck A/S	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
HK1258385A1 (zh)	2015-09-24	2019-11-08	泰瓦制药国际有限公司	预防、治疗和减轻(持续性)创伤後头痛
US20190071490A1 (en) *	2017-03-02	2019-03-07	Beth Israel Deaconess Medical Center, Inc.	Preventing Post-Ictal Headaches
US11752099B2 (en) *	2017-03-27	2023-09-12	W. L. Gore & Associates, Inc.	Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) *	2017-06-19	2018-12-27	President And Fellows Of Harvard College	Methods and compositions for treating a microbial infection
TWI754772B (zh) *	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
EP3908606A4 (en)	2019-01-08	2022-11-23	H. Lundbeck A/S	ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
PE20211708A1 (es)	2019-01-08	2021-09-01	H Lundbeck As	Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r

2012
- 2012-05-21 SM SM20190293T patent/SMT201900293T1/it unknown
- 2012-05-21 SG SG10201604040PA patent/SG10201604040PA/en unknown
- 2012-05-21 EA EA201891284A patent/EA201891284A1/ru unknown
- 2012-05-21 BR BR112013029932A patent/BR112013029932A2/pt not_active Application Discontinuation
- 2012-05-21 LT LTEP12789693.4T patent/LT2710039T/lt unknown
- 2012-05-21 ES ES19215303T patent/ES2873837T3/es active Active
- 2012-05-21 SI SI201231944T patent/SI3495392T1/sl unknown
- 2012-05-21 TR TR2019/04088T patent/TR201904088T4/tr unknown
- 2012-05-21 HR HRP20190640TT patent/HRP20190640T1/hr unknown
- 2012-05-21 WO PCT/US2012/038844 patent/WO2012162243A2/en not_active Ceased
- 2012-05-21 JP JP2014512923A patent/JP6282584B2/ja active Active
- 2012-05-21 HU HUE19215303A patent/HUE054437T2/hu unknown
- 2012-05-21 HU HUE12789693A patent/HUE044062T2/hu unknown
- 2012-05-21 AR ARP120101804A patent/AR086516A1/es active IP Right Grant
- 2012-05-21 PL PL18203518T patent/PL3495392T3/pl unknown
- 2012-05-21 KR KR1020137033843A patent/KR102128627B1/ko active Active
- 2012-05-21 CN CN201710902899.XA patent/CN107602700B/zh active Active
- 2012-05-21 CN CN201710917266.6A patent/CN107586338B/zh active Active
- 2012-05-21 ES ES18203518T patent/ES2893073T3/es active Active
- 2012-05-21 EP EP19215303.9A patent/EP3662932B1/en active Active
- 2012-05-21 PE PE2013002534A patent/PE20141787A1/es active IP Right Grant
- 2012-05-21 AU AU2012258966A patent/AU2012258966C1/en active Active
- 2012-05-21 LT LTEP19215303.9T patent/LT3662932T/lt unknown
- 2012-05-21 CN CN201280035733.8A patent/CN103748111B/zh active Active
- 2012-05-21 PE PE2018000036A patent/PE20180502A1/es unknown
- 2012-05-21 PL PL12789693T patent/PL2710039T3/pl unknown
- 2012-05-21 SM SM20210274T patent/SMT202100274T1/it unknown
- 2012-05-21 CN CN201810269398.7A patent/CN108424452B/zh active Active
- 2012-05-21 AP AP2013007259A patent/AP2013007259A0/xx unknown
- 2012-05-21 US US13/476,465 patent/US9745373B2/en active Active
- 2012-05-21 TW TW101118029A patent/TWI646111B/zh active
- 2012-05-21 PH PH1/2013/502405A patent/PH12013502405B1/en unknown
- 2012-05-21 TW TW106121803A patent/TWI685505B/zh active
- 2012-05-21 RS RS20211095A patent/RS62306B1/sr unknown
- 2012-05-21 EP EP22178673.4A patent/EP4115905A1/en active Pending
- 2012-05-21 DK DK12789693.4T patent/DK2710039T3/en active
- 2012-05-21 DK DK18203518.8T patent/DK3495392T3/da active
- 2012-05-21 CA CA3080000A patent/CA3080000A1/en active Pending
- 2012-05-21 SI SI201231586T patent/SI2710039T1/sl unknown
- 2012-05-21 SM SM20210526T patent/SMT202100526T1/it unknown
- 2012-05-21 PT PT12789693T patent/PT2710039T/pt unknown
- 2012-05-21 BR BR122022012930-7A patent/BR122022012930B1/pt active IP Right Grant
- 2012-05-21 SG SG2013084058A patent/SG194938A1/en unknown
- 2012-05-21 EP EP18203518.8A patent/EP3495392B1/en active Active
- 2012-05-21 LT LTEP18203518.8T patent/LT3495392T/lt unknown
- 2012-05-21 PL PL19215303T patent/PL3662932T3/pl unknown
- 2012-05-21 CA CA3079978A patent/CA3079978A1/en active Pending
- 2012-05-21 EP EP12789693.4A patent/EP2710039B1/en active Active
- 2012-05-21 EA EA201301295A patent/EA031065B1/ru unknown
- 2012-05-21 CA CA2836649A patent/CA2836649C/en active Active
- 2012-05-21 ES ES12789693T patent/ES2715001T3/es active Active
- 2012-05-21 EA EA201592042A patent/EA039905B1/ru unknown
- 2012-05-21 TW TW109110803A patent/TWI719869B/zh active
- 2012-05-21 MX MX2013013535A patent/MX370749B/es active IP Right Grant
- 2012-05-21 HU HUE18203518A patent/HUE055505T2/hu unknown
- 2012-05-21 DK DK19215303.9T patent/DK3662932T3/da active
- 2012-05-21 EP EP21159270.4A patent/EP3875115A1/en active Pending
- 2012-05-21 RS RS20190430A patent/RS58621B1/sr unknown
- 2012-05-21 TW TW107143050A patent/TWI692485B/zh active
- 2012-05-21 PT PT192153039T patent/PT3662932T/pt unknown
- 2012-05-21 RS RS20210554A patent/RS61793B1/sr unknown
- 2012-05-21 SI SI201231916T patent/SI3662932T1/sl unknown
- 2012-05-21 NZ NZ733060A patent/NZ733060A/en unknown
- 2012-05-21 CN CN201810269354.4A patent/CN108373502B/zh active Active
- 2012-05-21 PT PT182035188T patent/PT3495392T/pt unknown
2013
- 2013-11-14 IL IL229431A patent/IL229431B/en active IP Right Grant
- 2013-11-18 ZA ZA2013/08637A patent/ZA201308637B/en unknown
- 2013-11-19 MX MX2019015745A patent/MX2019015745A/es unknown
- 2013-11-19 MX MX2019008185A patent/MX2019008185A/es unknown
- 2013-11-20 CL CL2013003336A patent/CL2013003336A1/es unknown
- 2013-11-22 CO CO13275276A patent/CO6870005A2/es unknown
2016
- 2016-09-06 US US15/257,562 patent/US10066009B2/en active Active
2017
- 2017-05-30 CL CL2017001379A patent/CL2017001379A1/es unknown
- 2017-06-08 AU AU2017203890A patent/AU2017203890B2/en active Active
- 2017-08-24 JP JP2017160778A patent/JP6527563B2/ja active Active
2018
- 2018-02-09 US US15/892,892 patent/US10208112B2/en active Active
- 2018-02-09 US US15/892,804 patent/US10179809B2/en active Active
- 2018-02-09 US US15/892,956 patent/US10189895B2/en active Active
- 2018-02-09 US US15/892,858 patent/US10214582B2/en active Active
- 2018-03-09 PH PH12018500521A patent/PH12018500521A1/en unknown
- 2018-05-30 CL CL2018001452A patent/CL2018001452A1/es unknown
- 2018-08-30 US US16/117,401 patent/US10533048B2/en active Active
- 2018-09-25 IL IL26192718A patent/IL261927B/en active IP Right Grant
2019
- 2019-01-15 US US16/248,284 patent/US11111289B2/en active Active
- 2019-05-09 JP JP2019088960A patent/JP6952736B2/ja active Active
- 2019-08-04 IL IL268464A patent/IL268464B/en active IP Right Grant
- 2019-09-06 AU AU2019226231A patent/AU2019226231B2/en active Active
- 2019-11-03 IL IL270382A patent/IL270382B/en active IP Right Grant
2020
- 2020-01-13 US US16/740,699 patent/US20210047391A1/en not_active Abandoned
- 2020-04-06 AR ARP200100966A patent/AR118605A2/es unknown
2021
- 2021-05-11 CY CY20211100403T patent/CY1124209T1/el unknown
- 2021-05-14 HR HRP20210777TT patent/HRP20210777T1/hr unknown
- 2021-09-02 HR HRP20211395TT patent/HRP20211395T1/hr unknown
- 2021-09-21 CY CY20211100830T patent/CY1124515T1/el unknown
- 2021-10-21 AR ARP210102914A patent/AR123876A2/es unknown
2022
- 2022-06-13 NL NL301181C patent/NL301181I2/nl unknown
- 2022-06-20 LT LTPA2022511C patent/LTC3495392I2/lt unknown
- 2022-06-22 HU HUS2200031C patent/HUS2200031I1/hu unknown
- 2022-06-29 FR FR22C1032C patent/FR22C1032I2/fr active Active
- 2022-06-30 LU LU00270C patent/LUC00270I2/fr unknown
- 2022-07-08 NO NO2022029C patent/NO2022029I1/no unknown
2023
- 2023-07-05 US US18/346,961 patent/US20240174738A1/en active Pending

Also Published As

Publication number	Publication date
DK3495392T3 (da)	2021-09-13
TWI685505B (zh)	2020-02-21
CN107586338A (zh)	2018-01-16
JP2019150044A (ja)	2019-09-12
SI2710039T1 (sl)	2019-05-31
IL229431B (en)	2018-10-31
TW201936642A (zh)	2019-09-16
TR201904088T4 (tr)	2019-05-21
TW201300419A (zh)	2013-01-01
US10066009B2 (en)	2018-09-04
BR122022012930B1 (pt)	2023-10-10
US20190092842A1 (en)	2019-03-28
PH12018500521A1 (en)	2019-04-15
FR22C1032I1 (fr)	2022-09-09
TWI646111B (zh)	2019-01-01
MX370749B (es)	2019-12-20
CL2018001452A1 (es)	2018-08-10
IL261927A (en)	2018-10-31
EP2710039A2 (en)	2014-03-26
AU2012258966B2 (en)	2017-03-09
HRP20211395T1 (hr)	2021-12-10
RS62306B1 (sr)	2021-09-30
US20190211085A1 (en)	2019-07-11
CA3079978A1 (en)	2012-11-29
HUE054437T2 (hu)	2021-09-28
IL268464B (en)	2020-10-29
JP2018038391A (ja)	2018-03-15
CL2017001379A1 (es)	2017-12-29
ZA201308637B (en)	2022-11-30
CN103748111A (zh)	2014-04-23
DK2710039T3 (en)	2019-04-01
KR20140042819A (ko)	2014-04-07
IL229431A0 (en)	2014-01-30
CN108373502B (zh)	2022-03-22
HUE044062T2 (hu)	2019-09-30
EA201592042A1 (ru)	2016-03-31
LUC00270I2 (pl)	2025-04-25
PL3662932T3 (pl)	2021-09-06
AU2012258966C1 (en)	2022-02-03
CL2013003336A1 (es)	2014-06-06
LTC3495392I2 (pl)	2024-12-10
US10214582B2 (en)	2019-02-26
US20180215813A1 (en)	2018-08-02
CN108373502A (zh)	2018-08-07
NL301181I1 (pl)	2022-06-15
AU2019226231A1 (en)	2019-09-26
US11111289B2 (en)	2021-09-07
NO2022029I1 (no)	2022-07-08
CN108424452B (zh)	2021-08-03
NZ733060A (en)	2022-08-26
AR118605A2 (es)	2021-10-20
IL268464A (en)	2019-09-26
JP6282584B2 (ja)	2018-02-21
CA2836649C (en)	2020-06-23
WO2012162243A3 (en)	2013-01-17
LT2710039T (lt)	2019-04-25
MX2013013535A (es)	2015-08-20
ES2893073T3 (es)	2022-02-07
WO2012162243A2 (en)	2012-11-29
HRP20210777T1 (hr)	2021-06-25
CA3080000A1 (en)	2012-11-29
CY1124209T1 (el)	2022-05-27
CO6870005A2 (es)	2014-02-20
SG10201604040PA (en)	2016-07-28
US20210047391A1 (en)	2021-02-18
CN107586338B (zh)	2021-09-17
EP3875115A1 (en)	2021-09-08
PH12013502405B1 (en)	2018-11-07
SI3495392T1 (sl)	2021-11-30
PE20141787A1 (es)	2014-12-07
US20180215815A1 (en)	2018-08-02
EA039905B1 (ru)	2022-03-25
TW202033559A (zh)	2020-09-16
EA201301295A1 (ru)	2014-04-30
US10533048B2 (en)	2020-01-14
HRP20190640T1 (hr)	2019-05-31
NL301181I2 (nl)	2022-11-24
AU2017203890A1 (en)	2017-06-29
JP6527563B2 (ja)	2019-06-05
CA2836649A1 (en)	2012-11-29
US10189895B2 (en)	2019-01-29
IL261927B (en)	2019-11-28
KR102128627B1 (ko)	2020-06-30
US20180215814A1 (en)	2018-08-02
US20240174738A1 (en)	2024-05-30
US10208112B2 (en)	2019-02-19
AP2013007259A0 (en)	2013-11-30
PT2710039T (pt)	2019-04-23
NZ618637A (en)	2016-03-31
US20120294797A1 (en)	2012-11-22
PT3662932T (pt)	2021-05-14
JP2014517699A (ja)	2014-07-24
EP2710039A4 (en)	2014-11-19
RS61793B1 (sr)	2021-06-30
EA031065B1 (ru)	2018-11-30
US20170174754A1 (en)	2017-06-22
AR123876A2 (es)	2023-01-18
SI3662932T1 (sl)	2021-08-31
TW201811835A (zh)	2018-04-01
LT3495392T (lt)	2021-09-27
US10179809B2 (en)	2019-01-15
AU2017203890B2 (en)	2019-06-06
EP3495392B1 (en)	2021-08-18
US9745373B2 (en)	2017-08-29
SMT202100274T1 (it)	2021-07-12
NZ717570A (en)	2018-09-28
LTPA2022511I1 (pl)	2022-07-11
SG194938A1 (en)	2013-12-30
AU2019226231B2 (en)	2021-06-03
CY1124515T1 (el)	2022-07-22
RS58621B1 (sr)	2019-05-31
PL3495392T3 (pl)	2021-12-13
ES2873837T3 (es)	2021-11-04
EA201891284A1 (ru)	2018-11-30
EP2710039B1 (en)	2019-01-09
BR112013029932A2 (pt)	2017-01-31
EP3662932B1 (en)	2021-04-07
PE20180502A1 (es)	2018-03-09
CN107602700B (zh)	2021-12-17
TWI692485B (zh)	2020-05-01
IL270382B (en)	2020-11-30
PH12013502405A1 (en)	2014-02-10
EP3662932A1 (en)	2020-06-10
AR086516A1 (es)	2013-12-18
US20180215816A1 (en)	2018-08-02
HUS2200031I1 (hu)	2022-07-28
EP4115905A1 (en)	2023-01-11
CN108424452A (zh)	2018-08-21
CN103748111B (zh)	2018-04-27
MX2019015745A (es)	2020-02-13
PT3495392T (pt)	2021-09-22
MX2019008185A (es)	2019-09-09
JP6952736B2 (ja)	2021-10-20
SMT202100526T1 (it)	2021-11-12
DK3662932T3 (da)	2021-05-17
SMT201900293T1 (it)	2019-07-11
CN107602700A (zh)	2018-01-19
EP3495392A1 (en)	2019-06-12
ES2715001T3 (es)	2019-05-31
HUE055505T2 (hu)	2021-11-29
FR22C1032I2 (fr)	2023-06-02
TWI719869B (zh)	2021-02-21
LT3662932T (lt)	2021-06-10

Publication	Publication Date	Title
HUS2200031I1 (hu)	2022-07-28	Anti-CGRP készítmények és alkalmazásuk
IL230863A0 (en)	2014-03-31	Immunotherapeutic compositions of 1muc-shemer and their uses
IL230511A0 (en)	2014-03-31	4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
IL229844B (en)	2022-02-01	Anti-psgl-1 antibodies and their use
PL2771071T3 (pl)	2020-02-28	Kompozycje perfumeryjne i ich zastosowanie
GB201113770D0 (en)	2011-09-21	Novel compositions and uses thereof
ZA201404399B (en)	2015-12-23	Bio-pesticide methods and compositions
HUE041627T2 (hu)	2019-05-28	Tisztító készítmények és eljárások
IL232362A0 (en)	2014-06-30	The chemical composition containing fluorine and its use
GB201106357D0 (en)	2011-06-01	Composition and uses thereof
EP2668044A4 (en)	2015-11-25	COMPOSITIONS AND THEIR USE
ZA201308892B (en)	2016-08-31	Compositions and methods
GB201005826D0 (en)	2010-05-26	New compositions and their use
GB201120470D0 (en)	2012-01-11	Compositions and uses thereof
GB201101924D0 (en)	2011-03-23	Compositions and uses
GB201107454D0 (en)	2011-06-15	Compositions and uses
GB201116340D0 (en)	2011-11-02	Compositions and methods
IL231477A0 (en)	2014-04-30	Degradable vehicles and their use
LT3689878T (lt)	2021-11-25	4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai